HIV Infection in Portugal: Measuring the Time Between Linkage to Care and Antiretroviral Therapy Initiation
Abstract
1. Introduction
2. Materials and Methods
2.1. Data Collection
2.2. Variables
2.3. Data Analysis
2.4. Ethical Considerations
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A
- Portuguese HIV Study Group:
- Pedro Gomes Santos: Serviço de Medicina, Centro Hospitalar Universitário do Algarve EPE—Unidade de Faro, Faro, Portugal.
- Isabel Germano: Serviço de Medicina 1, Centro Hospitalar Universitário Lisboa Central (CHULC), EPE, Hospital de São José, Lisboa, Portugal.
- Ricardo Correia Abreu: Serviço de Doenças Infeciosas, ULS Matosinhos, EPE, Hospital Pedro Hispano, Senhora da Hora, Portugal.
- Isaac Pereira: Serviço de Medicina, ULS Baixo Alentejo, EPE—Hospital José Joaquim Fernandes, Beja, Portugal.
- André Almeida: Serviço de Medicina, Centro Hospitalar Universitário Lisboa Central (CHULC), EPE, Hospital de Santo António dos Capuchos, EPE, Lisboa, Portugal.
- Fausto Roxo: Unidade de Doenças Infeciosas, Hospital Distrital de Santarém, Santarém, Portugal.
- Pedro Martins: Serviço de Doenças Infeciosas, Centro Hospitalar do Tâmega e Sousa, Penafiel, Portugal.
- Raquel Diogo: Serviço de Doenças Infeciosas, Centro Hospitalar Universitário Lisboa Norte (CHULN), EPE, Hospital de Santa Maria, Lisboa, Portugal.
- Gonçalo Cristóvão: Serviço de Doenças Infeciosas, Centro Hospitalar Universitário Lisboa Central (CHULC), EPE, Hospital de Curry Cabral, Lisboa, Portugal.
- Carmela Piñeiro: Serviço de Doenças Infeciosas, Centro Hospitalar Universitário de São João (CHUSJ), EPE, Porto, Portugal.
- Nuno Marques: Serviço de Infeciologia, Hospital Garcia de Orta, EPE, Almada, Portugal.
- Ana Rodrigues: Serviço de Doenças Infeciosas, Hospital Professor Doutor Fernando da Fonseca, EPE, Amadora, Portugal.
- João Rodrigues: Serviço de Doenças Infeciosas, Centro Hospitalar Universitário de Santo António, EPE, Porto, Portugal.
- Joana Fragoso: Serviço de Doenças Infeciosas, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
- Miguel Rodrigues: Serviço de Medicina, Centro Hospitalar de Setúbal, EPE, Setúbal, Portugal.
- Filomena Freitas: Centro Hospitalar do Baixo Vouga, EPE, Aveiro, Portugal.
- Daniela Rodrigues: Serviço de Medicina, Centro Hospitalar Barreiro Montijo, EPE, Barreiro, Portugal.
- Liliana Pedro: Serviço de Medicina, Centro Hospitalar Universitário do Algarve EPE—Unidade de Portimão, Portimão, Portugal.
- Carla Tonel: Serviço de Medicina, Hospital Vila Franca de Xira, EPE, Vila Franca de Xira, Portugal.
- Álvaro Aires Pereira: Serviço de Doenças Infeciosas, Centro Hospitalar Universitário Lisboa Norte (CHULN), EPE, Hospital de Santa Maria, Lisboa, Portugal.
- Vasco Almeida: Serviço de Doenças Infeciosas, Centro Hospitalar Universitário Lisboa Central (CHULC), EPE, Hospital de Curry Cabral, Lisboa, Portugal.
References
- Hammer, S.M.; Squires, K.E.; Hughes, M.D.; Grimes, J.M.; Demeter, L.M.; Currier, J.S.; Eron, J.J.; Feinberg, J.E.; Balfour, H.H.; Deyton, L.R.; et al. A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimetre or Less. N. Engl. J. Med. 1997, 337, 725–733. [Google Scholar] [CrossRef] [PubMed]
- Palella, F.J.; Delaney, K.M.; Moorman, A.C.; Loveless, M.O.; Fuhrer, J.; Satten, G.A.; Aschman, D.J.; Holmberg, S.D. Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection. N. Engl. J. Med. 1998, 338, 853–860. [Google Scholar] [CrossRef] [PubMed]
- Mateo-Urdiales, A.; Johnson, S.; Smith, R.; Nachega, J.B.; Eshun-Wilson, I. Rapid Initiation of Antiretroviral Therapy for People Living with HIV. Cochrane Database Syst. Rev. 2019, 6, CD012962. [Google Scholar] [CrossRef] [PubMed]
- Kitahata, M.M.; Gange, S.J.; Abraham, A.G.; Merriman, B.; Saag, M.S.; Justice, A.C.; Hogg, R.S.; Deeks, S.G.; Eron, J.J.; Brooks, J.T.; et al. Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. N. Engl. J. Med. 2009, 360, 1815–1826. [Google Scholar] [CrossRef] [PubMed]
- Andrade, H.B.; Shinotsuka, C.R.; Da Silva, I.R.F.; Donini, C.S.; Li, H.Y.; De Carvalho, F.B.; Alvarenga Americano do Brasil, P.E.; Bozza, F.A.; Japiassu, A.M. Highly Active Antiretroviral Therapy for Critically Ill HIV Patients: A Systematic Review and Meta-Analysis. PLoS ONE 2017, 12, e0186968. [Google Scholar] [CrossRef] [PubMed]
- Lundgren, J.D.; Babiker, A.G.; Gordin, F.; Emery, S.; Grund, B.; Sharma, S.; Avihingsanon, A.-C.; Cooper, D.A.; Fätkenheuer, G.; Llibre, J.M.; et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N. Engl. J. Med. 2015, 373, 795–807. [Google Scholar] [CrossRef] [PubMed]
- Temprano ANRS 12136 Study Group. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N. Engl. J. Med. 2015, 373, 808–822. [Google Scholar] [CrossRef] [PubMed]
- Samji, H.; Cescon, A.; Hogg, R.S.; Modur, S.P.; Althoff, K.N.; Buchacz, K.; Burchell, A.N.; Cohen, M.; Gebo, K.A.; Gill, M.J.; et al. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLoS ONE 2013, 8, e81355. [Google Scholar] [CrossRef] [PubMed]
- Lohse, N.; Obel, N. Update of Survival for Persons with HIV Infection in Denmark. Ann. Intern. Med. 2016, 165, 749–750. [Google Scholar] [CrossRef] [PubMed]
- Gupta, A.; Verma, A.; Kashyap, M.; Gautam, P. ART in Prevention of Mother-to-Child Transmission of HIV. J. Obstet. Gynecol. India 2020, 70, 18–22. [Google Scholar] [CrossRef] [PubMed]
- Cohen, M.S.; Chen, Y.Q.; McCauley, M.; Gamble, T.; Hosseinipour, M.C.; Kumarasamy, N.; Hakim, J.G.; Kumwenda, J.; Grinsztejn, B.; Pilotto, J.H.S.; et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N. Engl. J. Med. 2011, 365, 493–505. [Google Scholar] [CrossRef] [PubMed]
- Zolopa, A.R.; Andersen, J.; Komarow, L.; Sanne, I.; Sanchez, A.; Hogg, E.; Suckow, C.; Powderly, W. Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial. PLoS ONE 2009, 4, e5575. [Google Scholar] [CrossRef] [PubMed]
- Koenig, S.P.; Dorvil, N.; Dévieux, J.G.; Hedt-Gauthier, B.L.; Riviere, C.; Faustin, M.; Lavoile, K.; Perodin, C.; Apollon, A.; Duverger, L.; et al. Same-Day HIV Testing with Initiation of Antiretroviral Therapy versus Standard Care for Persons Living with HIV: A Randomized Unblinded Trial. PLoS Med. 2017, 14, e1002357. [Google Scholar] [CrossRef] [PubMed]
- Pilcher, C.D.; Ospina-Norvell, C.; Dasgupta, A.; Jones, D.; Hartogensis, W.; Torres, S.; Calderon, F.; Demicco, E.; Geng, E.; Gandhi, M.; et al. The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting. J. Acquir. Immune Defic. Syndr. (1988) 2017, 74, 44–51. [Google Scholar] [CrossRef] [PubMed]
- Mendez-Lopez, A.; McKee, M.; Stuckler, D.; Granich, R.; Gupta, S.; Noori, T.; Semenza, J.C. Population Uptake and Effectiveness of Test-and-Treat Antiretroviral Therapy Guidelines for Preventing the Global Spread of HIV: An Ecological Cross-National Analysis. HIV Med. 2019, 20, 501–512. [Google Scholar] [CrossRef] [PubMed]
- Ford, N.; Migone, C.; Calmy, A.; Kerschberger, B.; Kanters, S.; Nsanzimana, S.; Mills, E.J.; Meintjes, G.; Vitoria, M.; Doherty, M.; et al. Benefits and Risks of Rapid Initiation of Antiretroviral Therapy. AIDS 2018, 32, 17–23. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy; World Health Organization: Geneva, Switzerland, 2017. [Google Scholar]
- Ford, N.; Vitoria, M.; Doherty, M. Providing Antiretroviral Therapy to All Who Are HIV Positive: The Clinical, Public Health and Programmatic Benefits of Treat All. J. Int. AIDS Soc. 2018, 21, e25078. [Google Scholar] [CrossRef] [PubMed]
- Njuguna, I.N.; Cranmer, L.M.; Otieno, V.O.; Mugo, C.; Okinyi, H.M.; Benki-Nugent, S.; Richardson, B.; Stern, J.; Maleche-Obimbo, E.; Wamalwa, D.C.; et al. Urgent versus Post-Stabilisation Antiretroviral Treatment in Hospitalised HIV-Infected Children in Kenya (PUSH): A Randomised Controlled Trial. Lancet HIV 2018, 5, e12–e22. [Google Scholar] [CrossRef] [PubMed]
- Grant, P.M.; Zolopa, A.R. When to Start ART in the Setting of Acute AIDS-Related Opportunistic Infections: The Time Is Now! Curr. HIV/AIDS Rep. 2012, 9, 251–258. [Google Scholar] [CrossRef] [PubMed]
- Boyd, M.A.; Boffito, M.; Castagna, A.; Estrada, V. Rapid Initiation of Antiretroviral Therapy at HIV Diagnosis: Definition, Process, Knowledge Gaps. HIV Med. 2019, 20, 3–11. [Google Scholar] [CrossRef] [PubMed]
- Bogdanić, N.; Bendig, L.; Lukas, D.; Zekan, Š.; Begovac, J. Timeliness of Antiretroviral Therapy Initiation in the Era before Universal Treatment. Sci. Rep. 2021, 11, 10508. [Google Scholar] [CrossRef] [PubMed]
- Joint United Nations Programme on HIV/AIDS. Prevailing Against Pandemics by Putting People at the Centre: World AIDS Day Report 2020; Joint United Nations Programme on HIV/AIDS: Geneva, Switzerland, 2020. [Google Scholar]
- Gardner, E.M.; McLees, M.P.; Steiner, J.F.; Del Rio, C.; Burman, W.J. The Spectrum of Engagement in HIV Care and Its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection. Clin. Infect. Dis. 2011, 52, 793–800. [Google Scholar] [CrossRef] [PubMed]
- Genberg, B.L.; Lee, Y.; Rogers, W.H.; Wilson, I.B. Four Types of Barriers to Adherence of Antiretroviral Therapy Are Associated with Decreased Adherence over Time. AIDS Behav. 2015, 19, 85–92. [Google Scholar] [CrossRef] [PubMed]
- Croome, N.; Ahluwalia, M.; Hughes, L.D.; Abas, M. Patient-Reported Barriers and Facilitators to Antiretroviral Adherence in Sub-Saharan Africa. AIDS 2017, 31, 995–1007. [Google Scholar] [CrossRef] [PubMed]
- Moges, N.A.; Adesina, O.A.; Okunlola, M.A.; Berhane, Y. Barriers and Facilitators of Same-Day Antiretroviral Therapy Initiation among People Newly Diagnosed with HIV in Ethiopia: Qualitative Study Using the Transtheoretical Model of Behavioral Change. J. Multidiscip. Healthc. 2020, 13, 1801–1815. [Google Scholar] [CrossRef] [PubMed]
- Patel, R.C.; Odoyo, J.; Anand, K.; Stanford-Moore, G.; Wakhungu, I.; Bukusi, E.A.; Baeten, J.M.; Brown, J.M. Facilitators and Barriers of Antiretroviral Therapy Initiation among HIV Discordant Couples in Kenya: Qualitative Insights from a Pre-Exposure Prophylaxis Implementation Study. PLoS ONE 2016, 11, e0168057. [Google Scholar] [CrossRef] [PubMed]
- Esber, A.L.; Coakley, P.; Ake, J.A.; Bahemana, E.; Adamu, Y.; Kiweewa, F.; Maswai, J.; Owuoth, J.; Robb, M.L.; Polyak, C.S.; et al. Decreasing Time to Antiretroviral Therapy Initiation after HIV Diagnosis in a Clinic-Based Observational Cohort Study in Four African Countries. J. Int. AIDS Soc. 2020, 23, e25446. [Google Scholar] [CrossRef] [PubMed]
- Medland, N.A.; Chow, E.P.F.; McMahon, J.H.; Elliott, J.H.; Hoy, J.F.; Fairley, C.K. Time from HIV Diagnosis to Commencement of Antiretroviral Therapy as an Indicator to Supplement the HIV Cascade: Dramatic Fall from 2011 to 2015. PLoS ONE 2017, 12, e0177634. [Google Scholar] [CrossRef] [PubMed]
- Lockman, S.; Holme, M.P.; Makhema, J.; Bachanas, P.; Moore, J.; Wirth, K.E.; Lebelonyane, R.; Essex, M. Implementation of Universal HIV Testing and Treatment to Reduce HIV Incidence in Botswana: The Ya Tsie Study. Curr. HIV/AIDS Rep. 2020, 17, 478–486. [Google Scholar] [CrossRef] [PubMed]
- Chen, Q.; Liu, J.; Fu, X.; Yang, F.; Liu, Q.; Li, J.; Tan, Z.; Li, J.; Lin, K.; Yan, Y.; et al. Effect of Late Testing and Antiretroviral Treatment on Mortality among People Living with HIV in the Era of Treat-All in Guangdong Province, China, 1992–2018: A Cohort Study. Front. Public Health 2022, 10, 851117. [Google Scholar] [CrossRef] [PubMed]
- Tao, Y.; Xiao, X.; Zhang, C.; Xie, Y.; Wang, H. Prevalence of Delayed Antiretroviral Therapy Initiation among People Living with HIV: A Systematic Review and Meta-Analysis. PLoS ONE 2023, 18, e0286476. [Google Scholar] [CrossRef] [PubMed]
- Alejos, B.; Díez, C.; Galindo, M.J.; Lopez, J.C.; Hernando, V.; Ayerdi, O.; Alonso, M.M.; Estrada, V.; Pineda, J.A.; Mena, A.; et al. Linkage to Care and Time to Viral Suppression in PWH in Spain: 2004–2020. Top. Antivir. Med. 2022, 30, 358. [Google Scholar]
- Hill, J.E.; Stephani, A.M.; Sapple, P.; Clegg, A.J. The Effectiveness of Continuous Quality Improvement for Developing Professional Practice and Improving Health Care Outcomes: A Systematic Review. Implement. Sci. 2020, 15, 23. [Google Scholar] [CrossRef] [PubMed]
- Powers, K.A.; Miller, W.C. Building on the HIV Cascade: A Complementary “HIV States and Transitions” Framework for Describing HIV Diagnosis, Care, and Treatment at the Population Level. J. Acquir. Immune Defic. Syndr. 2015, 69, 341–347. [Google Scholar] [CrossRef] [PubMed]
- Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90: An Ambitious Treatment Target to Help End the AIDS Epidemic; Joint United Nations Programme on HIV/AIDS: Geneva, Switzerland, 2014. [Google Scholar]
- Ministério da Saúde. Diário da República n.o 228/2015, 1o Suplemento, Série II de 2015-11-20, Despacho n.o 13447-C/2015; Ministério da Saúde: Lisboa, Portugal, 2015.
- Ministério da Saúde. Direção-Geral da Saúde Infeção VIH e SIDA: Desafios e Estratégias; Ministério da Saúde: Lisboa, Portugal, 2018.
- Nicolau, V.; Cortes, R.; Lopes, M.; Virgolino, A.; Santos, O.; Martins, A.; Faria, N.; Reis, A.P.; Santos, C.; Maltez, F.; et al. HIV Infection: Time from Diagnosis to Initiation of Antiretroviral Therapy in Portugal, a Multicentric Study. Healthcare 2021, 9, 797–810. [Google Scholar] [CrossRef] [PubMed]
- Gandhi, R.T.; Bedimo, R.; Hoy, J.F.; Landovitz, R.J.; Smith, D.M.; Eaton, E.F.; Lehmann, C.; Springer, S.A.; Sax, P.E.; Thompson, M.A.; et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA 2023, 329, 63–84. [Google Scholar] [CrossRef] [PubMed]
- Ministério da Saúde. Direção-Geral da Saúde; Instituto Nacional de Saúde Doutor Ricardo Jorge Infeção VIH e SIDA Em Portugal–2022; Ministério da Saúde: Lisboa, Portugal, 2022.
- Robertson, D.L.; Hahn, B.H.; Sharp, P.M. Recombination in AIDS Viruses. J. Mol. Evol. 1995, 40, 249–259. [Google Scholar] [CrossRef] [PubMed]
- Sharp, P.M.; Hahn, B.H. Origins of HIV and the AIDS Pandemic. Cold Spring Harb Perspect. Med. 2011, 1, a006841. [Google Scholar] [CrossRef] [PubMed]
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV; Department of Health and Human Services: Washington, DC, USA, 2024.
- Jespersen, S.; Månsson, F.; Lindman, J.; Wejse, C.; Medina, C.; da Silva, Z.J.; Te, D.; Medstrand, P.; Esbjörnsson, J.; Hønge, B.L. HIV Treatment in Guinea-Bissau: Room for Improvement and Time for New Treatment Options. AIDS Res. Ther. 2020, 17, 3. [Google Scholar] [CrossRef] [PubMed]
- European Centre for Disease Prevention and Control. HIV/AIDS Surveillance in Europe 2022–2021 Data; European Centre for Disease Prevention and Control: Stockholm, Sweden, 2022.
- European Centre for Disease Prevention and Control. ECDC Special Report: Continuum of HIV Care-Monitoring Implementation of the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2021 Progress Report; European Centre for Disease Prevention and Control: Stockholm, Sweden, 2021.
- Gregori, N.; Renzetti, S.; Izzo, I.; Faletti, G.; Fumarola, B.; degli Antoni, M.; Arsuffi, S.; Storti, S.; Tiecco, G.; Calza, S.; et al. Does the Rapid Initiation of Antiretroviral Therapy at HIV Diagnosis Impact Virological Response in a Real-Life Setting? A Single-Centre Experience in Northern Italy. AIDS Care 2023, 35, 1938–1947. [Google Scholar] [CrossRef] [PubMed]
- Ben Farhat, J.; Hessamfar, M.; Farbos, S.; Desclaux, A.; Dumondin, G.; Ferrand, H.; Greib, C.; Castan, B.; Rispal, P.; Duffau, P.; et al. Time to Treatment Initiation and HIV Viral Suppression in People Diagnosed with HIV-1 during COVID-19 Pandemic in Ex-Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliCOV Study). J. Acquir. Immune Defic. Syndr. (1988) 2024, 95, 1–5. [Google Scholar] [CrossRef] [PubMed]
- European Centre for Disease Prevention and Control. World AIDS Day 2022: WHO/Europe and ECDC Report Reveals Increasing Numbers Living with Undiagnosed HIV in the Region 2022; European Centre for Disease Prevention and Control: Stockholm, Sweden, 2022.
- Ogoina, D.; Finomo, F.; Harry, T.; Inatimi, O.; Ebuenyi, I.; Tariladei, W.; Afolayan, A.A. Factors Associated with Timing of Initiation of Antiretroviral Therapy among HIV-1 Infected Adults in the Niger Delta Region of Nigeria. PLoS ONE 2015, 10, e0125665. [Google Scholar] [CrossRef] [PubMed]
- Direção Geral da Saúde/Instituto Nacional de Saúde Doutor Ricardo Jorge. 2023; Unpublished data.
Year of the First Appointment | N | Median (IQR) | Mean (Standard Deviation) | Range (Minimum–Maximum) |
---|---|---|---|---|
2017 | 493 | 36.00 (33.00) | 48.74 (48.15) | 1–364 |
2018 | 497 | 30.00 (23.00) | 39.54 (36.59) | 1–309 |
2019 | 428 | 29.00 (30.50) | 39.73 (42.07) | 1–355 |
2020 | 348 | 21.00 (28.00) | 36.62 (46.83) | 1–351 |
2021 | 353 | 22.00 (23.00) | 31.99 (39.08) | 1–351 |
2022 | 110 | 21.00 (22.00) | 26.15 (27.73) | 1–222 |
Total | 2229 | 29.00 (30.00) | 39.30 (42.52) | 1–354 |
Total N | ≤14 Days n (%) | >14 Days n (%) | p-Value | |
---|---|---|---|---|
HIV stage | ||||
A | 1512 | 316 (60.3%) | 1196 (70.1%) | |
B | 458 | 104 (19.8%) | 354 (20.8%) | <0.001 |
C | 259 | 104 (19.8%) | 155 (9.1%) | |
Type of virus | ||||
HIV1 | 2190 | 514 (98.1%) | 1676 (98.3%) | |
HIV2 | 3 | 1 (0.2%) | 2 (0.1%) | 0.902 |
HIV1 and 2 | 36 | 9 (1.7%) | 27 (1.6%) | |
Viral load | ||||
Mean (SD) | 756,175 (4,409,505) | 1,1432,246 (4,927,177) | 637,216 (4,232,190) | |
Median (IQR) | 83,100 (319,702) | 138,000 (570,850) | 70,718 (245,472) | <0.001 |
Minimum–maximum | 0–101,000,000 | 37–100,000,000 | 0–101,000,000 | |
Initial TCD4+ cell count | ||||
Mean (SD) | 377.52 (331.06) | 328.01 (257.29) | 392.74 (349.28) | |
Median (IQR) | 338.00 (353) | 292.50 (367) | 353.23 (345) | <0.001 |
Minimum–maximum | 1–9210 | 1–1362 | 2–9210 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Virgolino, A.; Ferraz, C.; Nicolau, V.; Cortes, R.; Pereira, A.; Maltez, F.; Caldas, J.P.; Lourinho, J.; Alves, M.; Caetano, I.; et al. HIV Infection in Portugal: Measuring the Time Between Linkage to Care and Antiretroviral Therapy Initiation. Healthcare 2025, 13, 1812. https://doi.org/10.3390/healthcare13151812
Virgolino A, Ferraz C, Nicolau V, Cortes R, Pereira A, Maltez F, Caldas JP, Lourinho J, Alves M, Caetano I, et al. HIV Infection in Portugal: Measuring the Time Between Linkage to Care and Antiretroviral Therapy Initiation. Healthcare. 2025; 13(15):1812. https://doi.org/10.3390/healthcare13151812
Chicago/Turabian StyleVirgolino, Ana, Carolina Ferraz, Vanessa Nicolau, Rui Cortes, Aida Pereira, Fernando Maltez, João Paulo Caldas, João Lourinho, Maria Alves, Inês Caetano, and et al. 2025. "HIV Infection in Portugal: Measuring the Time Between Linkage to Care and Antiretroviral Therapy Initiation" Healthcare 13, no. 15: 1812. https://doi.org/10.3390/healthcare13151812
APA StyleVirgolino, A., Ferraz, C., Nicolau, V., Cortes, R., Pereira, A., Maltez, F., Caldas, J. P., Lourinho, J., Alves, M., Caetano, I., Teixeira, T., Casella, I., Soeiro, C., Meseiro, A., Pinho, R., Ribeiro, A., Serrão, R., Antunes, F., & on behalf of the Portuguese HIV Study Group. (2025). HIV Infection in Portugal: Measuring the Time Between Linkage to Care and Antiretroviral Therapy Initiation. Healthcare, 13(15), 1812. https://doi.org/10.3390/healthcare13151812